Anavex Life Sciences (AVXL)

• Market cap: $682M
• 1 day: -6.53%
• 5 days: -16.02%
• 1 month: -3.02%
• 3 months: -33.99%
• 6 months: 47.43%
• Year to date: -33.99%
• 1 year: 59.76%
• 5 years: 184.40%
• 10 years: -15.13%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Employees: 2

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

124% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 21

106% more capital invested

Capital invested by funds: $154M [Q3] → $316M (+$162M) [Q4]

63% more call options, than puts

Call options by funds: $15.9M | Put options by funds: $9.78M

23% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 40

17% more funds holding

Funds holding: 144 [Q3] → 168 (+24) [Q4]

2.95% more ownership

Funds ownership: 31.85% [Q3] → 34.8% (+2.95%) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $42 424% upside
• Avg. target: $44 449% upside
• High target: $46 474% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju 34% 1-year accuracy 117 / 342 met price target	424% upside $42	Buy Reiterated	31 Mar 2025
D. Boral Capital Jason Kolbert 30% 1-year accuracy 98 / 328 met price target	474% upside $46	Buy Maintained	12 Feb 2025